✦ LIBER ✦

309 THE PREDICTIVE VALUE OF CHROMOGRANIN A EXPRESSION FOR DOCETAXEL RESPONSE IN METASTATIC HORMONE REFRACTORY PROSTATE CANCER

✍ Scribed by A. Gernone; S. Trabucco; V. Pagliarulo; G. Troccoli; A. Pagliarulo

Book ID: 119617641
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 317 KB
Volume: 6
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(07)60308-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Chromogranin A Expression in Patients Wi

Chromogranin A Expression in Patients With Hormone Naïve Prostate Cancer Predicts the Development of Hormone Refractory Disease

✍ Berruti, Alfredo; Mosca, Alessandra; Porpiglia, Francesco; Bollito, Enrico; Tucc 📂 Article 📅 2007 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 235 KB

A systematic review of the effectiveness

A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer

✍ Collins, R; Trowman, R; Norman, G; Light, K; Birtle, A; Fenwick, E; Palmer, S; R 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 102 KB

UP-02.080 Prognostic Value of Chromogran

UP-02.080 Prognostic Value of Chromogranin A in Prostate Biopsy at the Moment of Diagnosis of Patients with Hormone-Refractory Prostate Cancer

✍ J. Casado Varela; I. Galante Romo; L. San José Manso; A. Hernando Arteche; M. Le 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 73 KB

UP-02.182 Prognostic Value of the Determ

UP-02.182 Prognostic Value of the Determination of Plasmatic Chromogranin A in Patients with Localized and Metastatic Hormone-Sensitive Prostate Cancer

✍ J. Casado Varela; L. San Jose Manso; I. Galante Romo; A. Hernando Arteche; H. Ga 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 81 KB

PCN83 Cost Effectiveness Analysis in the

PCN83 Cost Effectiveness Analysis in the Veneto Region of Cabazitaxel Versus Mitoxantrone in Patients with Metastatic Hormone Refractory Prostate Cancer, Previously Treated With a Docetaxel Containing Regimen

✍ P.R. Maran; A. Aiello; M.R. Magrì; C. Alberti; E. Visentin; F. Venturini; G. Scr 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

A phase 3 randomized controlled trial of

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer

✍ Michael A. Carducci; Fred Saad; Per-Anders Abrahamsson; David P. Dearnaley; Clau 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 2 views

## Abstract ## BACKGROUND. The objective of this study was to evaluate the efficacy and safety of atrasentan (Xinlay), a selective endothelin‐A receptor antagonist, in patients with metastatic hormone‐refractory prostate cancer (HRPC). ## METHODS. This multinational, double‐blind, placebo‐contro